Sign Up
Ready to replace complexity with clarity?
Answer your real world compliance questions (limited time) and save thousands in legal fees and avoided fines.
Automate Compliance TodayUS states A to Z: marijuana, THCA, delta-8, delta-9, delta-10, HHC
State-by-state mapMost read countries: marijuana, CBD and hemp status
All countries on the globeSubstances: status in every state for each one
Compare all substancesFederal hemp redefinition: P.L. 119-103, div. B, sec. 2019
Nov 12, 2026
Applies only to cannabinoids the plant cannot naturally produce.
Dec 11, 2026
The total-THC test, the 0.4 mg per container cap and the exclusion of converted cannabinoids start.
Latest regulatory actions, updated daily
All regulatory actionsHeadlines and the first four sentences are free. Full write-ups, impact reasoning and the archive are for members.
Member · $99/mo
Every rule change, the day it is made.
The price will rise. Join now and $99 a month stays your rate for life.
Become a memberOr read free: every action opens 30 days after it is published. Sign in with email
By topic
Licensing and permitsPackaging and labelingLab testing and QARetail complianceAdvertising and marketingBanking and paymentsTaxesShipping and logisticsTravel and transportLitigationSOPsFor your role
Regulators and agenciesBrands and operatorsRetailers and smoke shopsCultivatorsProcessorsLawyers and complianceInvestorsConsumers and travelersThe Regulator Brief · newsletter
Every rule change that matters, every Monday.
Free: the Monday brief, and every action 30 days after it is published.
Members: the paid weekly, daily alerts and every write-up.
Read by regulators, operators, lawyers and founders.
Cannabis lawyers
Licensed by state. Listings are not endorsements.
By state
Software and services
Compared by fit, never ranked.
Categories
For companies and firms
Be the listing operators and regulators find.
Software and services
Verified, $49/mo: domain-verified badge, your website link, a quote.
Featured, from $399/mo: labeled Featured in your category, monthly release notes.
Lawyers and firms
Claimed, $75/yr: Claimed badge and your firm's website link.
Featured, $199/mo: labeled Featured on your profile.
Claim your companyClaim a lawyer listingPlacements, flat monthly fee
State and country page sponsorshipsExclusive slot on a legality page and its postsRegulator Brief sponsorshipPresenting sponsor or mid-issue banner, free editionMember brief sponsor slotThe paid weekly, read by members onlyFeatured directory placementLabeled Featured in a software categoryCategory sponsorshipOwn one directory category across the sitePaid guest postsLabeled Paid guest post, sponsored linksWrite and partner
Pitch a paid guest postRead guest postsBecome an affiliateSend a tip or correctionContact the teamWho reads it
Regulators at federal, state and county agencies, plus the operators, lawyers and founders they regulate.
Get the media kitSee open placementsSubstances
US states, map and A to ZCountriesFederal hemp 2026: Nov 12 and Dec 11Compound index, every stateTravelling with cannabis or hempMembers get the daily alert email and every full write-up the morning it is published. Every action is free to read 30 days later.
For your role
All news and analysisGuidesAnalysisFAQsTemplates and SOPsCourt filing recapsNews by state and countrySoftware and services: Verified $49/mo, Featured from $399/mo. Lawyers and firms: Claimed $75/yr, Featured $199/mo. Listings are not endorsements.
Regulatory journalism, not legal advice. How we report
In 2025, the U.S. stands on the threshold of a historic regulatory shift: the likely move by the Drug Enforcement Administration (DEA) to reschedule cannabis to Schedule III under the Controlled Substances Act. While the much-anticipated administrative hearing was postponed in January, signals from major industry players and trade analysts as recently as August 2025 suggest the final rule is on the horizon.
But the era ahead isn’t a free-for-all. The ripple effects of federal rescheduling will bring a host of compliance changes and hidden challenges—and many things cannabis businesses hoped would change will still be controlled by other federal and state authorities. In this deep dive, we map out what changes on “Day One,” what stays the same, and provide a practical checklist for MSOs and hemp/cannabis brands to navigate the first 90 days after rescheduling.
The most celebrated, immediate impact of a move to Schedule III is the end of Internal Revenue Code §280E restrictions. Cannabis businesses—if operating in compliance with state law—will be able to deduct ordinary business expenses for the first time, aligning their tax treatment with other industries (Dope CFO, Yahoo Finance).
Expanded research opportunities will follow. Academic centers and the pharmaceutical sector will find it easier to conduct clinical studies with cannabis, leveraging new pathways that bypass many of the current DEA and FDA obstacles (Point of Care Nano).
Despite enthusiasm, rescheduling is NOT legalization. Adult-use cannabis remains federally illegal. State-licensed dispensaries and producers are not automatically shielded from federal action—though such enforcement is unlikely in the near term (Dentons).
Interstate commerce stays off the table. State programs, whether adult-use or medical, are not federally sanctioned. Interstate transfer or shipping of cannabis products remains risky and generally prohibited. Furthermore, rescheduling does not nullify state compliance regimes—everything from testing, packaging, advertising, marketing, and labeling rules will remain in place and enforced by state regulators (Dope CFO).
Rescheduling will make cannabis clients more attractive to insurers, as the Schedule I designation has long been cited as a barrier for coverage (Property Casualty 360). Look for more robust coverage offerings—but also for increased underwriting scrutiny around claims, product liability, and operational risks. Some insurers will expect enhanced compliance documentation.
Cannabis’ shift to Schedule III could ease but not erase banking compliance pressures. Financial institutions may see reduced risk under the Bank Secrecy Act, translating to fewer Suspicious Activity Report (SAR) filings, but most banks and credit unions will likely await further federal guidance before launching new cannabis lending and deposit products (Green Check Verified).
FDA will treat cannabis products (especially those with medical claims) much as it does controlled pharmaceuticals. Expect greater scrutiny of health, therapeutic, and wellness advertising—misleading claims could now trigger direct federal enforcement, and potentially criminal penalties. This also applies to product insert requirements, claims substantiation, and digital marketing controls (Hawke Media).
With cannabis in Schedule III, more U.S. universities, hospitals, and biotechs will partner with cannabis providers for clinical research. This unlocks NIH and private funding, but also subjects study protocols to DEA registration and FDA IND/IDE pathways. Quality controls, data integrity, and Good Clinical Practice (GCP) documentation become critical.
Pharmaceutical standards will begin to trickle into the cannabis sector. Batch-level documentation, QA/QC protocols, and facility certifications aligning with cGMP will become differentiators—and, over time, baseline requirements for pharmaceutical-grade cannabis or derivative products.
Rescheduling does not preempt state compliance frameworks. Every state—whether medical or adult-use—will continue to enforce:
State/local business, retailer, cultivation, and manufacturing licenses remain essential. No immediate changes to application windows, renewals, or social equity programs should be expected as a direct result of rescheduling.
Interstate transportation of cannabis remains a federal offense. Any product movement across state lines is still illegal, barring federal waivers not anticipated in 2025 or 2026. The Occupational Safety and Health Administration (OSHA) will continue to enforce worker safety, including impairment testing—no changes to drug-free workplace policies or post-accident drug screening (American Bar Association).
Stay ahead of the next compliance wave. For tailored, up-to-date state and federal cannabis compliance support, visit CannabisRegulations.ai and get clear answers as the regulatory landscape evolves in 2025–2026.